bsm-52042M [Primary Antibody]
CRISPR-Cas9 (1E8) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: CRISPR-Cas9

Clonality: Monoclonal

Isotype: IgM

Entrez Gene: 901176

Swiss Prot: Q99ZW2

Source: Recombinant fragment corresponding to Streptococcus pyogenes CRISPR-Cas9 (100-200aa)

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA) (Probable). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and this protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed by 3'-5' exonucleolytically. DNA-binding requires protein and both RNA species. Cas9 probably recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus nonself.

Size: 100ul

Concentration: 1ug/ul

Cross Reactive Species: Human
Others

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: 293T cells transfected with CRISPR9-Cas9; Lane 2: untransfected 293T cell lysate probed with CRISPR-Cas9 (1E8) Monoclonal Antibody, Unconjugated (bsm-52042M) at 1:1000 overnight at 4˚C. Followed by a conjugated secondary antibody.